Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Generating accurate in vitro intrinsic clearance data is an important aspect of predicting in vivo human clearance. Primary hepatocytes in suspension are routinely used to predict in vivo clearance; however, incubation times have typically been limited to 4–6 hours, which is not long enough to accurately evaluate the metabolic stability of slowly metabolized compounds. HepatoPac is a micropatterened hepatocyte-fibroblast coculture system that can be used for continuous incubations of up to 7 days. This study evaluated the ability of human HepatoPac to predict the in vivo clearance (CL) of 17 commercially available compounds with low to intermediate clearance (<12 ml/min/kg). In vitro half-life for disappearance of each compound was converted to hepatic clearance using the well stirred model, with and without correction for plasma protein binding. Hepatic CL, using three individual donors, was accurately predicted for 11 of 17 compounds (59%; predicted clearance within 2-fold of observed human in vivo clearance values). The accuracy of prediction increased to 82% (14 of 17 compounds) with an acceptance criterion defined as within 3-fold. When considering only low clearance compounds (<5 ml/min per kg), which represented 10 of the 17 compounds, the accuracy of prediction was 70% within 2-fold and 100% within 3-fold. In addition, the turnover of three slowly metabolized compounds (alprazolam, meloxicam, and tolbutamide) in HepatoPac was directly compared with turnover in suspended hepatocytes. The turnover of alprazolam and tolbutamide was approximately 2-fold greater using HepatoPac compared with suspended hepatocytes, which was roughly in line with the extrapolated values (correcting for the longer incubation time and lower cell number with HepatoPac). HepatoPac, but not suspended hepatocytes, demonstrated significant turnover of meloxicam. These results demonstrate the utility of HepatoPac for prediction of in vivo hepatic clearance, particularly with low clearance compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 2×
“, albumin secretion, urea synthesis, and drug metabolizing activities) (Khetani and Bhatia, 2008;Wang et al., 2010).”
BackgroundSelf-citationThe Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479 · cited 1×
“, lower clearance compounds suitable for once-daily dosing) (Carlile et al., 1997; Iwatsubo et al., 1997; Brandon et al., 2003; Fagerholm, 2007).”
BackgroundRodríguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., Castell, J. V., & Gómez-Lechón, M.-J. (2002) · Xenobiotica · doi:10.1080/00498250210128675 · Cited by 420
Andersson, T., Miners, J., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04336.x · Cited by 225
Ring, B. J., Chien, J. Y., Adkison, K. K., Jones, H. M., Rowland, M., Jones, R. D., Yates, J. W. T., Ku, M. S., Gibson, C. R., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22552 · Cited by 206 · cited 1×
“In this study the majority of compounds (6 of 9) were intermediate to high clearance (Ring et al., 2011).”
BackgroundPoulin, P., Kenny, J. R., Hop, C. E. C. A., & Haddad, S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22792 · Cited by 109 · cited 1×
“Several recent mathematical models that incorporate factors such as plasma albumin to liver albumin ratio and drug ionization may improve the ability to predict hepatocyte incubations, including HepatoPac, by reducing average prediction bias, but may not entirely eliminate it (Berezhkovskiy, 2011; Hallifax and Houston…”
BackgroundLavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Pharmaceutical Research · doi:10.1023/a:1012036324237 · Cited by 106 · cited 1×
“An alternative strategy that has been applied is to “bin” the CL prediction into categories of low, medium, or high clearance, which circumvents the challenges of accurately assessing the in vitro metabolic rates for low CL compounds (Wilkinson and Shand, 1975; Lavé et al., 1997).”
MethodBerezhkovskiy, L. M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22324 · Cited by 63
Cited by
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Primary Human Hepatocyte Spheroid Model as a 3D In Vitro Platform for Metabolism Studies
Kanebratt, K. P., Janefeldt, A., Vilén, L., Vildhede, A., Samuelsson, K., Milton, L., Björkbom, A., Persson, M., Leandersson, C., Andersson, T. B., et al. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.043 · Cited by 66
Preiss, L. C., Lauschke, V. M., Georgi, K., & Petersson, C. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00689-y · Cited by 36
“Also with MPCCs, CLb was predicted within 2-fold for 70% and within 3-fold for 100% of the 10 tested low clearance drugs (33), while single spheroids achieved CLb predictions within 3-fold for 86% of seven tested compounds with an AAFE of 1.”
Background
Metadata
- Authors
- Chan, T. S., Yu, H., Moore, A., Khetani, S. R., & Tweedie, D.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 47
- Issue
- 1
- Pages
- 58-66
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W4245629088
- Cited by
- 40
- References
- 11
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. https://app.cochat.ai/papers/10.1124/dmd.113.053397fullarticlecorrection
- The paper
- Chan, T. S., Yu, H., Moore, A., Khetani, S. R., & Tweedie, D. (2019). Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.113.053397fullarticlecorrection
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.